Sulbutiamine for Health & Longevity - Quick Reference Sheet

Sulbutiamine for Health & Longevity

Created on 09/25/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Grok 4 – Audit

Sulbutiamine, a fat-soluble made form of vitamin B1, is a medicine for low drive and tiredness in some countries and a dietary supplement in others. Studies enrolled tired, slowed, or ill people, not healthy adults seeking a longer life. Lasting benefit after infection was not shown. Day-to-day functioning can improve without a stronger effect on mood. The evidence is too thin to read it as an established longevity intervention. (Full Review)

Protocol

Labeled oral dose
400–600 mg a day
Adults; two or three 200 mg doses, administered orally with water. Pharmaceutical pattern, not a longevity protocol.
Split dosing and clock time
Morning and midday meals
Half-life about 5 hours; a single late dose is not the labeled pattern.
Course length
Four weeks
Label caps the course for physical or mental inhibition with low activity. Not presented as lifelong.
Time to effect
Functional scores in depression
Four weeks
Improved versus the comparison; depression scores did not.
Diabetic nerve conduction
Six weeks
Improved versus no added treatment in one unblinded comparison; symptom scores did not differ.
Fatigue signal
About one week
No difference at 28 days in the controlled comparison. An open series described a change at about two months. A lasting benefit is not established.

Benefits

Contraindications
  • Hypersensitivity to sulbutiamine or to an inactive ingredient, including sunset yellow E110 in Arcalion tablets
  • Breastfeeding
  • Pregnancy (any trimester); label prefers avoidance
  • Age under 18 years
  • Hereditary sugar-absorption disorders (galactose intolerance, fructose intolerance, sucrase-isomaltase deficiency) with Arcalion tablets; label discourages use
Key Interactions
  • Diuretics (furosemide, hydrochlorothiazide); severity: monitor
  • Neuromuscular blocking drugs (succinylcholine, rocuronium); severity: caution
  • Antacids and binding resins (calcium carbonate, colestipol, cholestyramine); severity: caution; labeled gap at least 2 hours
  • Macrogol laxatives (polyethylene glycol); severity: monitor; labeled gap at least 2 hours after the laxative
  • Cholinergic supplements (alpha-GPC, huperzine A); severity: theoretical caution

Risk & Side Effects

  • High:
  • Medium:
  • Low: Agitation, headache, tremor, nausea, vomiting, malaise, rash, stomach pain, diarrhea, insomnia; Overdose agitation; Disrupted care in bipolar disorder; Manic episode
  • Speculative: Sleep change at extreme doses

Monitoring

Marker Target Why
Thiamine diphosphate (whole blood or red cells) No sulbutiamine-specific target; track change from the person's own baseline Shows whether vitamin B1 cofactor stores were low at the start
Seated blood pressure Under 120/80 mmHg Agitation and malaise can travel with a higher pressure
Resting heart rate No sulbutiamine-specific target; track change from the person's own baseline Tremor and agitation may show up as a faster resting rate
Drive or fatigue rating (0–10) No established target; a better score than the person's own baseline The studied outcome is how the person functions, not a blood test
Pregnancy test Matters when pregnancy is possible The label prefers avoidance

Cadence: Before a first course, then at 1 week and at 4 weeks, the labeled maximum course. No studied schedule for multi-month longevity use. If use continues, the same checks every 3 months, sooner if agitation, rash, tremor, or insomnia appears.

Qualitative Assessment

  • Sleep onset and nighttime waking
  • Agitation, tremor, or headache
  • Nausea, stomach pain, or loose stools
  • Daytime drive and mental stamina
  • Rash or other skin change